Table 3.
Univariate and multivariate analysis to predict conversion surgery.
| Variables | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| Odds Ratio (95%CI) | p-Value | Odds Ratio (95%CI) | p-Value | |
| Pre-treatment factor | ||||
| Gender (male:female) | 1.162 (0.337–4.012) | 0.808 | ||
| Age, years (<70:≥70) | 2.848 (0.098–11.401) | 0.098 | ||
| Primary tumor site (Ph:Pbt) | 1.190 (0.327–4.065) | 0.783 | ||
| Radiological tumor size, mm (<40:≥40) | 1.071 (0.295–3.651) | 0.913 | ||
| NCCN resectability status of primary tumor (R/BR:UR) | 1.031 (0.147–4.524) | 0.971 | ||
| Peritoneal nodule (−:+) | 1.962 (0.565–6.843) | 0.282 | ||
| CA19-9, U/mL (<300:≥300) | 1.472 (0.434–5.340) | 0.535 | ||
| Post-treatment factor | ||||
| Normalization of CA19-9 (−:+) | 9.815 (2.378–66.86) | 0.001 | 7.537 (1.068–86.004) | 0.043 |
| Primary treatment (Ctrl: i.p.-PTX) | 7.121 (1.735–48.33) | 0.005 | 12.32 (1.831–142.92) | 0.008 |
| Response (CR/PR:SD/PD) | 69.00 (11.76–1326.3) | 0.001 | 62.47 (8.651–1381.3) | 0.001 |
Ph, pancreas head; Pbt, pancreas body and tail; NCCN, National Comprehensive Cancer Network; R, resectable; BR, borderline resectable; UR, unresectable; Ctrl, control; i.p.-PTX, intraperitoneal paclitaxel; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.